Summary.-Mice immunologically deprived by thymectomy, cytosine arabinoside treatment and whole-body irradiation were used to study the growth of human tumours as xenografts. 10/16 melanoma biopsies, 4/13 ovarian carcinoma biopsies and 3/6 uterine cancer biopsies grew as serially transplantable xenograft lines.
THERE is increasing interest in the growth of human tumours and xenografts in immunologically deprived mice, and in the use of these tumours to investigate the biology and therapy of human cancer. Ample data show that a substantial proportion of human tumours of some histological types may be grown in congenitally athymic "nude" mice (Rygaard & Povlsen, 1969; Second International Workshop on Nude Mice, 1977) or in normal mice deprived of T-lymphocyte function by thymectomy combined with irradiation, marrow reconstitution and/or anti-lymphocyte serum (Castro, 1972; Cobb & Mitchley, 1974; Berenbaum et al., 1974) .
Recently, in this laboratory, a new method of "T-deprivation" has been investigated. It has been found that the lethal effects of 900 rad whole-body irradiation may be prevented by treatment of the mouse with cytosine arabinoside (AraC) 200 mg/kg i.p. 2 days beforehand (Millar et al., 1978) . Mice may, therefore, be immune-deprived by thymectomy, AraC pretreatment and irradiation, and such mice have been shown to be receptive of xenografts from an established laboratory line (Steel et al., 1978) . We have investigated the establishment of a series of malignant human melanomas, ovarian carcinomas and uterine cancers in the AraC-pretreated mouse. The resulting tumours have been studied through serial passage by growth rate measurement, histology, histochemistry, electron microscopy, karyotyping and immune fluorescence for human antigens.
The tumours were established in order to investigate their chemosensitivity using clonogenic assays for human tumour cells. The results of these studies will be reported separately. New tumour implants were observed for at least 3 months for signs of tumour growth, and in this study a successful take was only recorded when a tumour successfully grew in the second passage.
Mice.-Male CBA/Ca/Lac mice bred at the Institute of Cancer Research breeding centre, Pollards Wood, were thymectomized at 4 weeks old and treated with 900 rad whole-body irradiation from a cobalt-60 source (30 rad/min) 3-6 weeks later. The lethal effects ofthis irradiation were prevented by an i.p. injection of 200 mg/kg AraC 2 days before irradiation. The animals were kept in a separate animal house, on heat-sterilised bedding and given acidified water to prevent multiplication of pseudomonads, a common source of fatal septicaemia. Apart from occasional outbreaks of such infection, over 90% of each batch survived throughout the experiments Tumour growth rates. -Tumours were measured for their largest and smallest superficial diameters using Vernier calipers and the volume of the tumours estimated from the formula 7r/6 d3, where d is the mean diameter.
Medial growth rates were estimated at a volume of 0 5 cm3 and a median time to reach that volume was estimated for each tumour.
Histology.-Tissues were fixed in formalin or in Bouin's fixative and stained by haematoxylin and eosin. Melanomas were stained for melanin with a Fontana silver impregnation technique. Where the latter was negative, frozen sections of the melanomas were stained histochemically for the enzyme dopa oxidase, part of the biosynthetic pathway for melanin. (These special stains were kindly used for us by Mrs Diana Mitchell of the Department of Histopathology, Royal Marsden Hospital.) Ascites tumours were examined as stained smears and viewed under phase contrast.
Electron microscopy.-For examination by electron microscopy, tumour tissue was fixed in 2% glutaraldehyde for 1 h at 4°C and post-fixed in 1% osmic acid. Both fixatives were phosphate buffered (0-05M, pH 7-2-7.4) and the osmolarity was adjusted to 350 mOs/l with sucrose. Specimens were then dehydrated with ethanol and embedded in epon/araldite. Thin sections were then stained with uranyl acetate and lead citrate and examined with a Philips EM400 electron microscope.
Chromosomes. (6) HX42 (4) HX45 (5) HX46 (8) HX47 (7) HX50 (5) HX52 (2) HX34*(18) HX56 (3) HX60 (2) HX61 (2) HX62 (2) HX63 (2) HX51 ( Sections were thoroughly washed, covered in buffered glycerol and a cover slip and examined under a fluorescence microscope. Experiments were controlled using normal mouse tissue, and non-specific binding was excluded from each experiment.
RESULTS
Take rates (Table I) Sixteen samples of metastatic malignant melanoma from various biopsy sites were implanted and 10 serially transplantable lines were established. Small nodules initially grew at the sites of implantation of 5 other tumours, but these subsequently regressed completely having reached less than 5 mm diameter. No clear relationship was observed between xenograft take and biopsy site, histology, or previous treatment of the implanted tumours. In 4/6 samples which failed to grow, there was insufficient material to graft into 5 mice so that the take rate of fully adequate biopsies would be 10/12. serial passage in the newly established HX34. Secondly, the numbers of mitoses per 30 high-power microscopic fields were counted to give an indication of mitotic frequency (Table III) . It can be seen that there was a tendency for mitotic frequency to increase with passage, and in HX34, HX47 and HX56 this increase was more than 5-fold. Most mitoses occurred in tumour cells rather than stromal cells, and the increased number of mitoses did not appear to be explained by a reduction in the number of stromal cells in each field. (1) 47 (2) 54 (4) 32 (1) 41 (2) 19 (3) 28 (1) 53 (2) 59 (1) 72 (1) 80 (2) 16 (1) 48 (4) HX47 also showed features typical of malignant melanoma, with numerous melanosomes. However, the melanosomes were more abnormal than those seen in HX41, without the classical elliptical shape or internal filamentous structure. Melanin granules and melanosomes were less numerous than in HX41, and some cells contained few or none. Cells were again heterogeneous in terms of melanin content, but no distinct sub-groups could be established. Macrophages were also seen in this tumour.
HX49 was quite different in ultrastructure. No melanin or melanosomes were seen, and cells were mononuclear, uniform, and contained large amounts of glycogen. Karyotypes All the melanoma xenografts, and HX49 and 60, had human karyotypes. The other ovarian tumour xenografts and the uterine tumour xenografts have not Table IV .
Immune fluorescence The xenografted melanomas were investigated by immune fluorescence, and human antigens were successfully demonstrated in sections cut from fixed and embedded tissues. It was not necessary to cut frozen sections to obtain satisfactory material for staining. Human tumour cells were readily distinguished from mouse stroma cells by this technique, but accurate quantification was not possible.
Growth rates
Volume growth curves were plotted for some passages of each of the melanoma and ovarian tumour xenografts. For all the tumours adequately assessed, the shape of the growth curves indicated progressively increasing volume-doubling times, and no initial exponential phase could be defined (Fig. 2) . This general shape was compatible with Gompertzian growth curves but no mathematical analysis was carried out.
As indications of the relative growth rates of xenografts, the median"volume- tumours, followed by growth (Fig. 2) . This pattern of initial regression was not seen in melanoma tumour xenografts. There was an impression that HX45, 47 and 50 grew more quickly in later passages, whilst HX40 grew more slowly. However, there was a large scatter in the data, so the differences were tested for significance by the Wilcoxon two-sample rank sum test to compare the doubling times of groups of tumours in each passage. Passages were only included in this analysis if data on the growth of more than 5 individual tumours were available.
HX45 and 46 were shown to grow significantly more quickly in the later passages, in terms of doubling time at a volume of 0 5 cm3 and in terms of the time taken to reach 0 5 cm3 that volume (P < 0.05). HX50 and 56 took significantly less time to grow to a volume of 0 5 cm3 in later passages, but their volumedoubling times were not significantly decreased. No significant changes occurred for HX40, 41, 42, 46 or 52.
DISCUSSION
The success rates for the establishment of transplantable xenograft lines from metastatic melanoma, ovarian cancer and uterine cancer in mice immune-depressed by thymectomy, AraC treatment and 900 rad whole-body irradiation were as good as those reported in other types of Tdeprived mice, or in nude, athymic mice (Povlsen, 1976; Kullander et al., 1978; Berenbaum et al., 1974) . Metastatic melanoma appeared to produce a higher take rate than metastatic ovarian cancer, but the difference was not statistically significant using a x2 test with Yates' correction for small numbers. Preliminary results in this laboratory with other histological types of cancer, including testicular teratoma, oat-cell carcinoma of the bronchus, colo-rectal carcinoma and pancreatic tumours, indicate these are also quite readily established as transplantable xenograft lines in mice immune-deprived by thymectomy, AraC and irradiation (unpublished observations by Mr Andrew Shorthouse, Dr Derek Ragavan and Mr John G(ibbs). These results suggest that this method of immune deprivation may prove at least as useful as irradiation with marrow reconstitution for the growth of human tumour xenografts, and it is also a simpler procedure. However, it is known that T-deprived mice may recover their immune competence 6-8 weeks after irradiation (Steel et al., 1978) which may be a limitation in some types of experiment.
Ascitic ovarian tumours were not successfully xenografted in this study in 5 attempts. This observation is in keeping with the findings of Kullander et al. (1978) that solid ovarian tumours grew as xenografts in nude mice but that cell suspensions from these tumours and ascitic ovarian tumours were much less successful. Whether these results are due to poor viability of the ascitic cells or to the presence of large numbers of inflammatory cells is unclear.
The data suggest that the xenografts here described maintained many important biological characteristics of human cancer through serial passage. All retained their human karyotypes and human antigens. It is known that subtle changes in karyotype may occur with serial xenograft passage (Reeves & Houghton, 1978) but detection of these requires the use of banding techniques which were not used in the present studies.
Histologically the xenografted tumours resembled their original tumours, apart from changes in the stromal content. The stroma was shown to be of mouse origin in the immuno-fluorescence studies. In the endometrial adenocarcinomas of the uterus there seemed to be a tendency for loss of differentiation with serial passage. This tendency to differentiate has also been seen in a testicular teratoma xenograft during serial passage, using immunoperoxidase staining for HCG and measurement of HCG in mouse serum (Selby et al., 1979) . However, other workers have not found loss of differentiation with passage (Houghton & Taylor, 1978a; Sharkey et at., 1977) .
Two of the melanoma xenografts lost pigmentation during serial passage, as has previously been observed (Mukherji et al., 1974; Shimosato et al., 1976) . The significance of this change is not certain. It could represent selection of a sub-population of amelanotic cells or a phenotypic variation due to the growth environment of the cells. Since pigment production is a differentiated function of melanocytes, loss of this may represent a loss of differentiation similar to that seen in the uterine carcinomas and in the testicular teratoma.
The ultrastructure of the melanoma xenografts was similar to that described by other authors for malignant melanoma (Hunter et al., 1978) and classical melanosomes were seen. However, the original biopsies of these tumours were not examined by electron microscopy, so direct comparison is not possible.
The measurements of growth rates suggested that the melanoma xenografts grew more quickly than in the patients. Volumedoubling times of melanoma lung metastases are of the order of 50 days (Steel, 1977) . However, the lung metastases measured were usually larger than 05 cm3, and their growth may have slowed if they grew according to Gompertzian growth curves. The data on the ovarian tumour xenografts in the present study are much less complete and data from clinical measurements are also scanty, probably because lung metastases of ovarian carcinomas are unusual. Comparisons for the ovarian carcinomas are therefore probably not worthwhile. A tendency for xenografted tumours to increase in volume more quickly than tumours in situ has been described in other tumour types (Lamerton & Steel, 1975) . Some of the melanoma xenografts appeared to grow more quickly in later passages, and this has been previously reported in some xenografted tumours of colo-rectal cancer (Houghton & Taylor, 1978b) and stomach cancer (Takahashi et al., 1977) . This increase in growth rate with serial passage has been attributed to a decrease in cell loss rather than to an increase in cell proliferation within the tumours (Lamerton & Steel, 1975; Houghton & Taylor, 1978b) . This explanation would not be supported by the observation in the present study that mitotic frequency increased with passage in most of the tumours studied. However, mitotic index is a notoriously unreliable measurement, and confirmation of this would require more extensive studies of the cellproliferation kinetics of these tumours.
This study has shown that the thymectomized, AraC-pretreated and irradiated mouse can readily be used to establish a series of human tumour xenografts, of at least some histological types. These tumours appeared to retain the charactersistics of human tumours to a substantial extent. However, some changes were observed in degree of differentiation, pigmentation, growth rate and mitotic frequency, and these emphasise the need for careful assessment of xenografted tumours when they are used as models of human cancer.
